Glofitamab with GemOx for diffuse large B-cell lymphoma – Authors' reply

Jeremy S. Abramson; Matthew Ku; Gareth P. Gregory; Christopher P. Fox

doi:10.1016/S0140-6736(25)01583-1

Glofitamab with GemOx for diffuse large B-cell lymphoma – Authors' reply

Jeremy S. Abramson
, Matthew Ku
, Gareth P. Gregory
, Christopher P. Fox

Medicine Monash Health

Research output: Contribution to journal › Letter › Other › peer-review

Original language	English
Pages (from-to)	1727-1728
Number of pages	2
Journal	The Lancet
Volume	406
Issue number	10513
DOIs	https://doi.org/10.1016/S0140-6736(25)01583-1
Publication status	Published - 18 Oct 2025

Access to Document

10.1016/S0140-6736(25)01583-1

Cite this

@article{79ad41dd5f1b41dc8ffe891bcec4ffff,

title = "Glofitamab with GemOx for diffuse large B-cell lymphoma – Authors' reply",

author = "Abramson, \{Jeremy S.\} and Matthew Ku and Gregory, \{Gareth P.\} and Fox, \{Christopher P.\}",

year = "2025",

month = oct,

day = "18",

doi = "10.1016/S0140-6736(25)01583-1",

language = "English",

volume = "406",

pages = "1727--1728",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "10513",

}

TY - JOUR

T1 - Glofitamab with GemOx for diffuse large B-cell lymphoma – Authors' reply

AU - Abramson, Jeremy S.

AU - Ku, Matthew

AU - Gregory, Gareth P.

AU - Fox, Christopher P.

PY - 2025/10/18

Y1 - 2025/10/18

UR - https://www.scopus.com/pages/publications/105019114667

U2 - 10.1016/S0140-6736(25)01583-1

DO - 10.1016/S0140-6736(25)01583-1

M3 - Letter

C2 - 41109716

AN - SCOPUS:105019114667

SN - 0140-6736

VL - 406

SP - 1727

EP - 1728

JO - The Lancet

JF - The Lancet

IS - 10513

ER -

Glofitamab with GemOx for diffuse large B-cell lymphoma – Authors' reply

Access to Document

Other files and links

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Cite this